301 related articles for article (PubMed ID: 8124262)
21. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
[TBL] [Abstract][Full Text] [Related]
22. T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow.
Janossy G; Prentice HG; Grob JP; Ivory K; Tidman N; Grundy J; Favrot M; Brenner MK; Campana D; Blacklock HA
Clin Exp Immunol; 1986 Mar; 63(3):577-86. PubMed ID: 3011326
[TBL] [Abstract][Full Text] [Related]
23. Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients.
Herve P
J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074
[TBL] [Abstract][Full Text] [Related]
24. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
25. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH
J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703
[TBL] [Abstract][Full Text] [Related]
26. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
27. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
Marciniak E; Romond EH; Thompson JS; Henslee PJ
Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
29. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.
Soiffer RJ; Weller E; Alyea EP; Mauch P; Webb IL; Fisher DC; Freedman AS; Schlossman RL; Gribben J; Lee S; Anderson KC; Marcus K; Stone RM; Antin JH; Ritz J
J Clin Oncol; 2001 Feb; 19(4):1152-9. PubMed ID: 11181681
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
31. Measurement of recipient-specific alloreactivity: is GVHD predictable?
Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
[TBL] [Abstract][Full Text] [Related]
32. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
33. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
35. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
36. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow transplantation in miniature swine. III. Graft-versus-host disease and the effect of T cell depletion of marrow.
Sakamoto K; Sachs DH; Shimada S; Popitz-Bergez FA; Pennington LR; Pescovitz MD; McDonough MA; MacVittie TJ; Katz SI; Gress RE
Transplantation; 1988 May; 45(5):869-75. PubMed ID: 3285532
[TBL] [Abstract][Full Text] [Related]
38. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients.
Bosserman LD; Murray C; Takvorian T; Anderson KC; Freedman AS; Fitzsimmons J; Coral F; Nadler LM; Schlossman SF; Ritz J
Bone Marrow Transplant; 1989 May; 4(3):239-45. PubMed ID: 2659109
[TBL] [Abstract][Full Text] [Related]
40. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
